AU2022312986A1 - Annulated pyridazine compound - Google Patents

Annulated pyridazine compound Download PDF

Info

Publication number
AU2022312986A1
AU2022312986A1 AU2022312986A AU2022312986A AU2022312986A1 AU 2022312986 A1 AU2022312986 A1 AU 2022312986A1 AU 2022312986 A AU2022312986 A AU 2022312986A AU 2022312986 A AU2022312986 A AU 2022312986A AU 2022312986 A1 AU2022312986 A1 AU 2022312986A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
salt
amino
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022312986A
Other languages
English (en)
Inventor
Yusuke INAGAKI
Yoshinori Iwai
Takashi Kamikubo
Takanori Koike
Yuka KOIZUMI
Kazuyuki Kuramoto
Ikumi Kuriwaki
Junko Maeda
Akihiko Nakamura
Kengo SABA
Hiroshi Tomiyama
Hiroki Toya
Takuya Washio
Susumu Yamaki
Yumi Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tenvie Therapeutics Inc
Original Assignee
Nico Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nico Therapeutics Inc filed Critical Nico Therapeutics Inc
Publication of AU2022312986A1 publication Critical patent/AU2022312986A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022312986A 2021-07-21 2022-07-20 Annulated pyridazine compound Pending AU2022312986A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021120560 2021-07-21
JP2021-120560 2021-07-21
PCT/JP2022/028138 WO2023003002A1 (ja) 2021-07-21 2022-07-20 縮環ピリダジン化合物

Publications (1)

Publication Number Publication Date
AU2022312986A1 true AU2022312986A1 (en) 2024-03-07

Family

ID=84980224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022312986A Pending AU2022312986A1 (en) 2021-07-21 2022-07-20 Annulated pyridazine compound

Country Status (11)

Country Link
US (1) US20250084092A1 (https=)
EP (1) EP4375274A4 (https=)
JP (1) JPWO2023003002A1 (https=)
KR (1) KR20240059614A (https=)
CN (1) CN118234711A (https=)
AU (1) AU2022312986A1 (https=)
CA (1) CA3226995A1 (https=)
IL (1) IL310264A (https=)
MX (1) MX2024000984A (https=)
TW (1) TW202319055A (https=)
WO (1) WO2023003002A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL310992A (en) 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
US20240391881A1 (en) * 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
CN116102535A (zh) 2021-10-22 2023-05-12 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
WO2023088856A1 (en) 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
EP4499646A4 (en) * 2022-03-31 2026-03-18 Hangzhou Highlightll Pharmaceutical Co Ltd NLRP3 Inflammasome Inhibitors
AR129012A1 (es) * 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024109922A1 (zh) * 2022-11-25 2024-05-30 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
EP4655303A1 (en) * 2023-01-26 2025-12-03 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
CN120957980A (zh) 2023-01-31 2025-11-14 詹森药业有限公司 作为nlrp3抑制剂的2-(哒嗪-3-基)-5-(三氟甲基)苯酚
CN120659791A (zh) * 2023-04-17 2025-09-16 上海拓界生物医药科技有限公司 稠合哒嗪类衍生物及其用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
NZ760129A (en) 2017-07-07 2025-12-19 Inflazome Ltd Novel sulfonamide carboxamide compounds
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
AU2020358000A1 (en) 2019-10-04 2022-04-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP7356683B2 (ja) 2020-01-31 2023-10-05 東京パワーテクノロジー株式会社 ガスタービンの分解方法、組立方法、及び、治具
AR121669A1 (es) 2020-03-27 2022-06-29 Astellas Pharma Inc Compuesto de piridazina sustituida
CN116390914A (zh) * 2020-12-25 2023-07-04 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022253326A1 (zh) * 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
US20240327413A1 (en) * 2021-06-29 2024-10-03 Zomagen Biosciences Ltd Nlrp3 modulators
HRP20251513T1 (hr) 2021-07-02 2026-01-02 Astrazeneca Ab Inhibitori inflamasoma nlrp3
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
US20240391881A1 (en) * 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
CN116102535A (zh) * 2021-10-22 2023-05-12 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
AR129012A1 (es) * 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados

Also Published As

Publication number Publication date
EP4375274A4 (en) 2025-08-06
MX2024000984A (es) 2024-06-19
TW202319055A (zh) 2023-05-16
JPWO2023003002A1 (https=) 2023-01-26
CN118234711A (zh) 2024-06-21
WO2023003002A1 (ja) 2023-01-26
US20250084092A1 (en) 2025-03-13
CA3226995A1 (en) 2023-01-26
EP4375274A1 (en) 2024-05-29
IL310264A (en) 2024-03-01
KR20240059614A (ko) 2024-05-07

Similar Documents

Publication Publication Date Title
AU2022312986A1 (en) Annulated pyridazine compound
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
AU2016355710B2 (en) Modulators of ROR-gamma
AU2022267160A1 (en) Substituted triazine compound
WO2024041606A1 (zh) 具有抗kras突变肿瘤活性的化合物
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
AU2017209935B2 (en) New substituted cyanoindoline derivatives as NIK inhibitors
CN101903385B (zh) 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
WO2014173291A1 (zh) 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
WO2013026025A1 (en) Cyclohexyl azetidine derivatives as jak inhibitors
CN105164114A (zh) C-连接的杂环烷基取代的嘧啶类和它们的用途
CN118772176A (zh) 一种嘧啶并芳环化合物及其制备方法和用途
CA2828478A1 (en) Serine/threonine kinase inhibitors
EP4610258A1 (en) Fused pyridazine derivative
CN118302417A (zh) Nlrp3抑制剂
CN106565706B (zh) 一种磺酰胺衍生物及其在药学中的应用
TW202409015A (zh) 一種prmt5抑制劑、其製備方法及應用
TW200951136A (en) Furo[3,2-d]pyrimidine derivatives
CN113045569A (zh) 用作ret激酶抑制剂的化合物及其应用
TWI894448B (zh) Ctla-4小分子降解劑及其應用
WO2023155900A1 (zh) 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途
CN105636962B (zh) 新型化合物、用途及其制备方法
WO2023155710A1 (zh) Ikzf2降解剂及包含其的药物组合物和用途
WO2009056551A1 (en) Furo[3,2-d]pyrimidine derivatives
KR102958021B1 (ko) 피리다지닐 티아졸카르복시아미드 화합물